Literature DB >> 10205207

Accuracy of screening for gastric cancer using serum pepsinogen concentrations.

F Kitahara1, K Kobayashi, T Sato, Y Kojima, T Araki, M A Fujino.   

Abstract

BACKGROUND/AIMS: The characteristics of pepsinogen screening for gastric cancer were investigated to establish a suitable cut off point for identifying gastric cancer, using endoscopic diagnosis as the yardstick. SUBJECTS/
METHODS: Serum pepsinogen concentrations were measured in 5113 subjects who were also screened for gastric cancer by endoscopy. The cut off point for pepsinogen was determined using receiver operator characteristics curves.
RESULTS: The most suitable cut off point was a pepsinogen I concentration of less than 70 ng/ml and a ratio of pepsinogen I to pepsinogen II of less than 3. 0. Using this cut off point, the sensitivity and specificity of pepsinogen screening for gastric cancer were 84.6% and 73.5% respectively. All cases of gastric cancer in patients with severe atrophic gastritis were detected. However, two of four cases of gastric cancer in patients with mild atrophic gastritis were overlooked. In subjects with mild atrophic gastritis, when gastric cancer arises within the fundic gland region, the size of the lesion determines whether it is possible to detect cancer by serum pepsinogen screening.
CONCLUSION: Pepsinogen screening has many advantages, including its suitability for combination with other screening methods because it is simple and inexpensive.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205207      PMCID: PMC1727514          DOI: 10.1136/gut.44.5.693

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  [Mass screening of stomach neoplasms by serum pepsinogen analysis].

Authors:  K Miki
Journal:  Nihon Naika Gakkai Zasshi       Date:  1992-05-10

2.  [Estimation of frequency, population doses and stochastic risks in stomach mass screening examinations in Japan, 1980].

Authors:  T Maruyama; Y Noda; Y Kumamoto; K Nishizawa; Y Furuya; K Iwai; S Urahashi; R Kurihara; R Kamata; S Sakata
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  1987-07-25

3.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia.

Authors:  I M Samloff; K Varis; T Ihamaki; M Siurala; J I Rotter
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

4.  Serum pepsinogen in screening for gastric cancer.

Authors:  A Kodoi; M Yoshihara; K Sumii; K Haruma; G Kajiyama
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

5.  Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis.

Authors:  F Sitas; R Smallwood; D Jewell; P R Millard; D G Newell; S G Meuwissen; S Moses; A Zwiers; D Forman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Mar-Apr       Impact factor: 4.254

6.  Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders.

Authors:  M Ichinose; K Miki; C Furihata; T Kageyama; R Hayashi; H Niwa; H Oka; T Matsushima; K Takahashi
Journal:  Clin Chim Acta       Date:  1982-12-09       Impact factor: 3.786

7.  Serum pepsinogens I and II and stomach cancer.

Authors:  G N Stemmermann; I M Samloff; A M Nomura; L K Heilbrun
Journal:  Clin Chim Acta       Date:  1987-03-16       Impact factor: 3.786

8.  The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group.

Authors:  P M Webb; K J Hengels; H Møller; D G Newell; D Palli; J B Elder; M P Coleman; G De Backer; D Forman
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

9.  [Clinical significance of the measurement of serum pepsinogen group I and II by enzyme-linked immunosorbent assay].

Authors:  K Matsumoto; K Hashimoto; T Samori; M Taniguchi; K Kotera; S Nishi; M Takatsuji; K Higashi; K Itoh
Journal:  Rinsho Byori       Date:  1992-09

10.  Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer.

Authors:  K Miki; M Ichinose; K B Ishikawa; N Yahagi; M Matsushima; N Kakei; S Tsukada; M Kido; S Ishihama; Y Shimizu
Journal:  Jpn J Cancer Res       Date:  1993-10
View more
  69 in total

1.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

2.  Significance of a novel sucrose permeability test using serum in the diagnosis of early gastric cancer.

Authors:  Tadayuki Shishido; Taketo Yamaguchi; Takeo Odaka; Masanori Seimiya; Hiromitsu Saisho; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

3.  Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer.

Authors:  Akira Sekikawa; Hirokazu Fukui; Ryota Sada; Manabu Fukuhara; Saiko Marui; Gensho Tanke; Masatsugu Endo; Yoshiaki Ohara; Fumihiro Matsuda; Jun Nakajima; Shinichiro Henmi; Sumio Saito; Takehiko Tsumura; Takanori Maruo; Toru Kimura; Yukio Osaki
Journal:  J Gastroenterol       Date:  2015-04-23       Impact factor: 7.527

4.  Biomarkers in various types of atrophic gastritis and their diagnostic usefulness.

Authors:  Kazimierz Rembiasz; Peter C Konturek; Danuta Karcz; Stanislaw J Konturek; Władysław Ochmanski; Wladyslaw Bielanski; Andrzej Budzynski; Jerzy Stachura
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

5.  Validation of the pepsinogen test method for gastric cancer screening using a follow-up study.

Authors:  Shigeto Mizuno; Masao Kobayashi; Shohken Tomita; Ikuya Miki; Atsuhiro Masuda; Mitsuko Onoyama; Yasuki Habu; Hideto Inokuchi; Yoshiyuki Watanabe
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

6.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

7.  Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis.

Authors:  Yoshihisa Urita; Kazuo Hike; Naotaka Torii; Yoshinori Kikuchi; Eiko Kanda; Masahiko Sasajima; Kazumasa Miki
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

8.  The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy.

Authors:  Akiko Shiotani; Takashi Sakakibara; Yoshiyuki Yamanaka; Ryuji Nishi; Hiroshi Imamura; Minoru Fujita; Ken-ichi Tarumi; Tomoari Kamada; Jiro Hata; Ken Haruma
Journal:  J Gastroenterol       Date:  2009-05-16       Impact factor: 7.527

9.  Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication.

Authors:  Katsunori Iijima; Tomoyuki Koike; Yasuhiko Abe; Nobuyuki Ara; Kaname Uno; Akira Imatani; Shuichi Ohara; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2009-05-14       Impact factor: 7.527

10.  Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.

Authors:  Mitsuru Kaise; Jun Miwa; Ai Fujimoto; Jun Tashiro; Daisuke Tagami; Hiromi Sano; Yasukazu Ohmoto
Journal:  Gastric Cancer       Date:  2012-08-21       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.